ARTICLE | Clinical News
Ecarin clotting time test regulatory update
May 22, 2000 7:00 AM UTC
PHAR received a humanitarian device exemption from the FDA for its ECT to manage patients with heparin induced thrombocytopenia (HIT) who receive Aventis S.A.'s Refludan lepirudin thrombin inhibitor...